230 related articles for article (PubMed ID: 10912573)
1. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.
Tetef ML; Margolin KA; Doroshow JH; Akman S; Leong LA; Morgan RJ; Raschko JW; Slatkin N; Somlo G; Longmate JA; Carroll MI; Newman EM
Cancer Chemother Pharmacol; 2000; 46(1):19-26. PubMed ID: 10912573
[TBL] [Abstract][Full Text] [Related]
2. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
[TBL] [Abstract][Full Text] [Related]
3. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis.
Mehta BM; Glass JP; Shapiro WR
Cancer Res; 1983 Jan; 43(1):435-8. PubMed ID: 6600162
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
[TBL] [Abstract][Full Text] [Related]
5. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
6. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
9. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
Glantz MJ; Cole BF; Recht L; Akerley W; Mills P; Saris S; Hochberg F; Calabresi P; Egorin MJ
J Clin Oncol; 1998 Apr; 16(4):1561-7. PubMed ID: 9552066
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of methotrexate in the cerebrospinal fluid after intracerebroventricular administration in patients with meningeal carcinomatosis and altered cerebrospinal fluid flow dynamics.
Miller KT; Wilkinson DS
Ther Drug Monit; 1989; 11(3):231-7. PubMed ID: 2728081
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of methotrexate in systemic tissues after intrathecal administration.
Bleyer WA; Nelson JA; Kamen BA
J Pediatr Hematol Oncol; 1997; 19(6):530-2. PubMed ID: 9407940
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.
Pignon T; Lacarelle B; Duffaud F; Guillet P; Catalin J; Durand A; Monjanel S; Favre R
Cancer Chemother Pharmacol; 1994; 33(5):420-4. PubMed ID: 8306417
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
15. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
16. The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy.
Allen J; Rosen G; Juergens H; Mehta B
J Neurooncol; 1983; 1(1):39-44. PubMed ID: 6611387
[TBL] [Abstract][Full Text] [Related]
17. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
[TBL] [Abstract][Full Text] [Related]
18. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
19. [Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis].
Kullmann T; Gauthier H; le Maignan C; Szabó A; Culine S
Orv Hetil; 2012 Sep; 153(35):1385-8. PubMed ID: 22935431
[TBL] [Abstract][Full Text] [Related]
20. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]